Annual report pursuant to Section 13 and 15(d)

Organization and Summary of Significant Accounting Policies (Details)

v2.4.0.6
Organization and Summary of Significant Accounting Policies (Details) (USD $)
 12 Months Ended
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2010
Organization And Summary Of Accounting Policies [Line Items]      
Fair value of notes payable $ 9,700,000    
Debt issuance costs   593,000  
Amortization of deferred debt issuance costs 296,000 2,000 4,000
Deferred debt issuance costs 295,000 591,000  
Estimated tax liability from gain on sale of discontinued operation   6,700,000  
Estimated tax liability from income of discontinued operation   1,200,000 2,100,000
Estimated income tax benefit    $ 7,880,143 $ 2,134,903
Minimum [Member]
      
Organization And Summary Of Accounting Policies [Line Items]      
Useful Life 3 years    
Estimated useful lives, patent costs 5 years    
Maximum [Member]
      
Organization And Summary Of Accounting Policies [Line Items]      
Useful Life 7 years    
Estimated useful lives, patent costs 15 years    
The 1996 Plan [Member]
      
Organization And Summary Of Accounting Policies [Line Items]      
Shares authorized under share-based compensation plan 1,500,000    
The 2002 Plan [Member]
      
Organization And Summary Of Accounting Policies [Line Items]      
Shares authorized under share-based compensation plan 12,000,000    
Cira Bio [Member]
      
Organization And Summary Of Accounting Policies [Line Items]      
Ownership percentage 90.00%    
Navidia Biopharmaceuticals Limited [Member]
      
Organization And Summary Of Accounting Policies [Line Items]      
Ownership percentage 100.00%